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To the Editor;
Controversy persists on the benefit and extent of par-
aaortic lymph node dissection (PALND) in patients 
with endometrioid endometrial carcinoma (EC). Mor-
bidity (lymphedema, cellulitis), cost and increased 
operation time are major disadvantages of PALND. 
ASTEC trial did not demonstrate survival benefit favor-
ing lymphadenectomy.1 On the other hand, retrospective 
SEPAL study showed disease free survival and overall 
survival benefit with PALND in intermediate and high 
risk patients with uterine cancer. Risk assessment was 
based on disease stage, histological subtype, grade and 
lymph-vascular space invasion (LVSI) in this study.2 
Recently Kumar et al showed 3 independent predic-
tors of paraaortic metastases or recurrence (PAMR) in 
patients with endometrioid EC; Positive pelvic nodes, 
>50% myometrial invasion and lymphovascular space 
invasion. Given the low reliability of pelvic lymph 
nodes and LVSI in intra-operative frozen section, they 
found that omitting PALND in all patients with ≤50% 
myometrial invasion would affect 84% (792/946 pa-
tients) of the total cohort with a 1.1% risk of PAMR.3 
We have assessed the utility of outer myometrial inva-
sion as a criterion for omitting PALND in our patients 
with endometrioid EC diagnosed and operated between 
2007 and 2012 (n= 330) at Baskent University Hospi-
tal, Ankara, Turkey. All patients had undergone com-
prehensive surgical staging including pelvic-paraaortic 
lymph node dissection. Median number of pelvic lymph 
nodes removed was 30 and para-aortic lymph nodes 
was 7. Median tumor size was 3 cm (range 0.1 - 18 cm). 
Histological grade was 1 in 176 patients (53%), 2 in 118 
patients (36%) and 3 in 36 patients (11%). Ten patients 
(3%) had paraaortic lymph node metastases (PALNM). 
Among 218 patients with no or inner myometrial in-
volvement, none had PALNM while 10 of 102 patients 
(8.9%) with outer ½ involvement had PALNM. Median 
follow up was 29 months. 13 patients had recurrence on 
follow up. Only two patients had paraaortic nodal recur-
rence, both had outer myometrial invasion on primary 
surgery pathology. One of the patients had isolated par-
aaortic nodal recurrence 20 months after first diagno-
sis and was treated with chemoradiation and currently 
disease-free 2 years post-radiotherapy. Second patient 
had multiple bone metastases and paraaortic nodal re-
currence 8 months after the first diagnosis and died 15 
months thereafter. Therefore, our data is consistent with 
the study of Kumar et al. In our series, 218/330 (66 %) 
of the patients could be spared from PALND based on 
the extent of myometrial involvement alone given that 
none of these patients had PALNM on surgical staging 
and none had paraaortic nodal recurrence on follow-up. 
In a comprehensively staged population of patients with 
endometrioid EC, we suggest that absence of outer MI 
can reliably identify patients in whom PALND can be 
omitted safely. Algorithms incorporating this and other 
parameters can help surgeons tailor the need for lym-
phadenectomy and identify a subgroup who can be 
treated with more conservative surgery.
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